The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - AstraZeneca; Debiopharm Group; MSD; Roche
A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC.
 
A. Dimitrios Dimitrios Colevas
Consulting or Advisory Role - Alpha BioCom; Beigene; ClearView Healthcare Partners; Deallus; Gilead Sciences; leidos biomedical research
Research Funding - Abbvie; AstraZeneca; Atara Biotherapeutics; BioNtech; BMS; CUE Biopharma; Cullinan Oncology; Exelixis; Experimental Therapeutics Clinical Trials Network (ETCTN); Forty Seven; Innate Pharma; Merck; NIH/NCI; NRG Oncology; Tessa Therapeutics
 
José Dinis
No Relationships to Disclose
 
Venessa T Chin
No Relationships to Disclose
 
Diogo Alpuim Costa
Employment - NTT Data (I)
Consulting or Advisory Role - Nestle Health Science; Novartis; Pfizer
Speakers' Bureau - Merck; MSD; Nestle Health Science; Novartis
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Daiichi Sankyo Pharmaceutical; Gilead Sciences
 
John J. Park
No Relationships to Disclose
 
Bruno Fang
Employment - Astera Cancer Care
Leadership - Astera Cancer Care
Research Funding - Abbvie; Arvinas; Bristol-Myers Squibb/Pfizer; Daiichi Sankyo/Astra Zeneca; Epizyme; Exelixis; Gilead/Forty Seven; ImmunityBio; Janssen Oncology; Mirati Therapeutics; natera; Novartis; Novocure; POINT Biopharma; Roche/Genentech; Veru; Zymeworks; Zymeworks
 
Minh Duc Phan
No Relationships to Disclose
 
Yiran Zhang
Employment - Amgen; Gilead Sciences
Stock and Other Ownership Interests - Amgen
 
Lance U'Ren
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Jared Odegard
Employment - Gilead Sciences; Silverback Therapeutics (I)
Leadership - Abata Therapeutics (I); Odyssey Therapeutics (I); Silverback Therapeutics (I)
Stock and Other Ownership Interests - Abata Therapeutics (I); Gilead Sciences; Odyssey Therapeutics (I); Silverback Therapeutics (I)
 
Kelly Kevelin Curtis
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
Travel, Accommodations, Expenses - Gilead Sciences
 
Erika Pirtle
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Douglas Adkins
Consulting or Advisory Role - Boehringer Ingelheim; Calliditas Therapeutics; CUE Biopharma; Eisai Europe; Exelixis; Genmab/Seattle Genetics; Gilead Sciences; Immunitas; Jazz Pharmaceuticals; Kura Oncology; Merck; Seagen; TargImmune Therapeutics; Vaccinex
Research Funding - Adlai Nortye (Inst); AstraZeneca (Inst); BeiGene (Inst); BioAtla (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calliditas Therapeutics (Inst); Celgene (Inst); Cofactor Genomics (Inst); CUE Biopharma (Inst); Debiopharm Group (Inst); Epizyme (Inst); Genmab (Inst); Gilead Sciences (Inst); Hookipa Biotech (Inst); Immutep (Inst); ISA Pharmaceuticals (Inst); Kura Oncology (Inst); Lilly (Inst); Merck (Inst); NATCO Pharma (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst); Tizona Therapeutics, Inc. (Inst); Vaccinex (Inst)